
X
$2bn deal sees uniQure license haemophilia B gene therapy to CSL Behring
https://pharmaphorum.com/news/2bn-deal-sees-uniqure-license-haemophilia-b-gene-therapy-to-csl-behring/
French pharma makes move into haemophilia market.
Decision based on promising data from ongoing phase 1/2 trial.